Azenta

Azenta, Inc. is a provider of life sciences sample exploration and management solutions for the life sciences market. It operates through the Life Sciences Products and Life Sciences Services segments. The Life Sciences Products segment is involved in automated cold storage solutions for biological and chemical compound samples. The Life Sciences Services segment focuses on the solutions addressing the many needs of customers in the area of genomic analysis and the management and care of biological samples used in pharmaceutical, biotech, healthcare, clinical, and academic research, and development markets. The company was founded in 1978 and is headquartered in Burlington, MA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Azenta (AZTA) reports robust Q1 earnings, eyes strategic investments

Azenta's Q1 results showcase strong revenue growth and strategic acquisitions, positioning the company for future success. While facing challenges in certain segments, the focus on investments and efficiencies presents opportunities for growth and margin improvement.

Azenta reports mixed Q2 results, focuses on growth initiatives

Azenta's Q2 2023 performance was mixed, with challenges in B Medical impacting revenue but Services business showing resilience and genomics revenue rebounding positively.
Strategic acquisitions, cost actions, and a realignment initiative aim to enhance profitability and drive growth, with a focus on accelerating organic growth and expanding Services business.
Despite margin decreases and revenue challenges, Azenta remains focused on growth initiatives, addressing concerns about distractions and emphasizing opportunities for expansion and profitability.
Management's outlook includes revised revenue guidance, adjusted EBITDA margin expectations, and a commitment to driving profitability through growth initiatives and cost actions.

Azenta reports solid Q3 earnings, eyes growth in China

Azenta's Q3 performance showcased positive financial indicators, with notable growth in key segments and a focus on cost reduction initiatives.
While facing challenges in the Products segment and market share determination, the company remains optimistic about growth opportunities in China and key service offerings.
With a strong focus on sales, marketing, and cost reduction, Azenta aims to sustain its growth trajectory and enhance profitability in the future.

Azenta reports robust Q4 earnings, eyes growth opportunities in 2024

Azenta's Q4 performance was strong, with positive outlook for fiscal 2024 and a commitment to share repurchase.
While facing challenges in gross margins, the company sees opportunities in organic growth and margin expansion.
Strengthening Cell and Gene Therapy business and operational improvements are key focus areas for future growth.
Overall, Azenta remains confident in its ability to outperform the market and enhance profitability.

Azenta reports Q1 revenue decline but sees growth opportunities ahead

Azenta's Q1 performance showed mixed results with revenue decline but growth in key segments. The company remains focused on maintaining guidance and balancing revenue throughout the year.
While facing challenges in B Medical revenue and market dynamics, Azenta has opportunities in sample retrieval programs and financial performance improvements.
Overall, Azenta's strategic focus on key segments and opportunities for growth position the company well for future success, despite current challenges and market conditions.

Azenta reports solid Q2 earnings, eyes growth in China

Azenta's Q2 performance showed revenue growth and improved margins despite challenges.
The company's strengths lie in strong segment growth and market outperformance in China.
Challenges include lower guidance for B Medical and softness in the Instruments segment.
Opportunities arise from pursuing Ascend 2026 plan, NGS shift, and China market growth.

Azenta reports strong Q3 performance and operational profitability growth

Azenta's Q3 results reflect a positive trajectory with revenue growth and improved profitability.
Strategic focus on key segments and the Ascend 2026 program are driving operational efficiency and margin expansion.
While challenges exist in certain segments, opportunities for growth and optimization present a promising outlook for Azenta.

Azenta reports resilient Q4 performance and outlines growth strategies

Azenta's Q4 2024 earnings call highlighted strong financial results, strategic decisions, and future growth initiatives amidst market challenges and uncertainties.
The company's focus on core businesses, competitive strengths in Sample Management Solutions and Multiomics, and commitment to shareholder value enhancement position it for success in 2025.
While facing revenue declines and market-related queries, Azenta's proactive approach to portfolio optimization, operational efficiency, and capital allocation sets the stage for sustainable growth and profitability.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Disney

Having activist investors at a company can lead to big changes. Azenta is dealing with an activist's call for better performance as it puts a giant cash hoard to work.

You Can't Control Activist Investors, but You Can Control What You Do About Them

Azenta is sitting on a pile of cash, and shareholders will want to know the company's plans for the money.

Activist Politan Capital engages with Azenta. Here's how the firm may boost shareholder value

Becton, Dickinson and Co.

Industry Veteran Herman Cueto Named CFO Azenta CFO Lindon Robertson to Retire Company Reaffirms Guidance for Fourth Quarter Fiscal 2023 BURLINGTON, Mass. , Sept. 26, 2023 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that Herman Cueto will join Azenta as Executive Vice President and Chief Financial Officer, effective October 16.

Azenta Announces CFO Transition

BURLINGTON, Mass. , Sept. 8, 2023 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that Company management will participate in the Morgan Stanley 21st Annual Global Healthcare Conference in New York, NY, on Wednesday, September 13, 2023, which includes a presentation beginning at 2:55 pm ET.

Azenta to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference

BURLINGTON, Mass. , Sept. 7, 2023 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that Company management will participate in the Baird 2023 Global Healthcare Conference in New York, NY, on Tuesday, September 12, 2023, which includes a presentation beginning at 9:05 am ET.

Azenta to Participate in the Baird 2023 Global Healthcare Conference

Thermo Fisher Scientific

Waters

Here's a look at 3 leading robo-lab company stocks. When you think of dexterous professions, you often think of doctors or musicians.

Robo-Lab Stocks: 3 Robotics Companies Changing the Research Game

Twist Bioscience Corp

DNA is as fundamental to biotechnology as it is to biology itself. From synthetic biology to pharmaceuticals, making and using DNA is usually a necessary first step in bringing a biotech product to market.

Biotech Bonanza: 3 Top DNA Stocks With Revolutionary Potential

BURLINGTON, Mass. , Aug. 10, 2023 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that Company management will participate in the UBS MedTech, Tools and Genomics Summit 2023 in Dana Point, CA, on Tuesday, August 15, 2023, which includes a presentation beginning at 3:00 pm PT.

Azenta to Participate in the UBS MedTech, Tools and Genomics Summit 2023

BURLINGTON, Mass. , Aug. 9, 2023 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that Company management will participate in the 8th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference on Monday, August 14, 2023.

Azenta to Participate in the 8th Annual Needham Virtual MedTech & Diagnostics 1X1 Conference

Azenta, Inc. (NASDAQ:AZTA ) Q2 2023 Earnings Conference Call August 8, 2023 4:30 AM ET Company Participants Sara Silverman - Head of IR Steve Schwartz - President and CEO Lindon Robertson - CFO Conference Call Participants David Saxon - Needham Vijay Kumar - Evercore ISI Yuan Zhi - B. Riley FBR Operator Greetings, and welcome to the Azenta Q3, 2023 Financial Results.

Azenta, Inc. (AZTA) Q2 2023 Earnings Call Transcript

Azenta (AZTA) came out with quarterly earnings of $0.13 per share, beating the Zacks Consensus Estimate of a loss of $0.03 per share. This compares to earnings of $0.12 per share a year ago.

Azenta (AZTA) Beats Q3 Earnings and Revenue Estimates

BURLINGTON, Mass. , Aug. 8, 2023 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today reported financial results for the third quarter ended June 30, 2023.

Azenta Reports Results of Third Quarter of Fiscal 2023, Ended June 30, 2023

BURLINGTON, Mass. , Aug. 3, 2023 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) will announce fiscal third quarter 2023 earnings which ended on June 30, 2023 on Tuesday August 8, 2023 after the market closes.

Azenta Announces Fiscal 2023 Third Quarter Earnings Conference Call and Webcast

Azenta Life Sciences, a key player in the life sciences industry, is poised for financial recovery with a robust Q2 performance and cost-cutting measures, making it an enticing investment opportunity. The company's product portfolio includes automated sample storage systems, consumables, and genomics services, with recent innovations like Cryo Store Pico, designed for the efficient preservation of biological specimens. Despite potential limitations and competition, Azenta outperforms rivals through reliable innovation, strategic partnerships, and diverse offerings that prioritize individual client needs and optimize their research capabilities.

Azenta: Delivering Solid Growth In Life Sciences

Azenta has selected the greater Boston area, a key pharma and biotech hub, as the next location to expand its global biorepository footprint. BURLINGTON, Mass.

Azenta Announces New Biorepository in the Greater Boston Area

Today, we take our second look at a life sciences concern called Azenta, Inc. The company has a massive cash hoard, is buying back a huge amount of stock, but sales growth is slowing, and valuations appear stretched even after a recent pullback. An updated investment analysis around Azenta, Inc. follows in the paragraphs below.

Azenta: A Second Assessment

NANJING, China , May 31, 2023 /PRNewswire/ -- Vazyme (688105.SH), China's leading biotechnology company, has officially signed a global strategic cooperation agreement with Azenta Life Sciences ("Azenta", Nasdaq: AZTA), which will promote to establish "one-stop" service process for both companies in the fields of next-generation sequencing, automated library preparation, raw material supply, experimental consumables, sample storage and more. Dr. Nie Junwei, General Manager of Life Science Division, Vazyme, and Mr.

Vazyme Signs Global Strategic Cooperation Agreement with Azenta

BURLINGTON, Mass. , May 30, 2023 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that Company management will participate in the Jefferies Healthcare Conference in New York, NY, on Thursday, June 8, 2023, which includes a presentation beginning at 11:30 am ET.

Azenta to Participate in the Jefferies Healthcare Conference

Azenta has been Selected by the Lupus Research Alliance as its Sample Management Services Provider and Partner in Supporting the Development of the Patient Registry Component of the Lupus Nexus BURLINGTON, Mass. , May 24, 2023 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced it has been selected by the Lupus Research Alliance and its clinical research affiliate Lupus Therapeutics to support the development of the patient registry component of the Lupus Nexus, which aims to advance and accelerate lupus research and drug discovery through information exchange capabilities.

Azenta Announces Collaboration with the Lupus Research Alliance to Support the Advancement of Lupus Research and Drug Discovery

BURLINGTON, Mass. , May 17, 2023 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that Company management will participate in the 23rd Annual B.

Azenta to Participate in the 23rd Annual B. Riley Securities Institutional Investor Conference

Azenta (AZTA) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to earnings of $0.12 per share a year ago.

Azenta (AZTA) Reports Q2 Loss, Misses Revenue Estimates

BURLINGTON, Mass. , May 9, 2023 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today reported financial results for the second quarter ended March 31, 2023.

Azenta Reports Results of Second Quarter of Fiscal 2023 and Announces Business Realignment

BURLINGTON, Mass. , May 3, 2023 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) will announce fiscal second quarter 2023 earnings which ended on March 31, 2023 on Tuesday, May 9, 2023 after the market closes.

Azenta Announces Fiscal 2023 Second Quarter Earnings Conference Call and Webcast

BURLINGTON, Mass. , April 13, 2023 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that Company management will participate in the 22nd Annual Needham Virtual Healthcare Conference on Tuesday, April 18, 2023, which includes a presentation beginning at 9:30 am ET.

Azenta to Participate in the 22nd Annual Needham Virtual Healthcare Conference

SkyQuest's Barcode Scanner market report is excellent information for individuals interested in gaining insight into the valuable data, trends, and opportunities in a rapidly growing industry. Additionally, the report is written clearly and concisely, making it accessible to various audiences, from industry experts to market readers. Finally, one can gain an in-depth understanding of the primary and secondary market drivers, providing them with a comprehensive outlook of the current market situation and future projections. SkyQuest's Barcode Scanner market report is excellent information for individuals interested in gaining insight into the valuable data, trends, and opportunities in a rapidly growing industry. Additionally, the report is written clearly and concisely, making it accessible to various audiences, from industry experts to market readers. Finally, one can gain an in-depth understanding of the primary and secondary market drivers, providing them with a comprehensive outlook of the current market situation and future projections.

News for Azenta Stock (AZTA)